Literature DB >> 18336841

Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.

Terry W Moody1, Tapas Pradhan, Samuel A Mantey, Robert T Jensen, Marcin Dyba, Deborah Moody, Nadya I Tarasova, Christopher J Michejda.   

Abstract

Hemiasterlin (Hem) and dolastatin (Dol) are marine natural products which are cytotoxic for cancer cells. Hem, a tripeptide, and Dol, a hexapeptide, were conjugated with linkers (L) to the universal BB agonist DPhe-Gln-Trp-Ala-Val-betaAla-His-Phe-Nle-NH2(BA1) and the effects of the Hem-BB and Dol-BB conjugates investigated on NCI-H1299 lung cancer cells. Hem-LA-BA1 and Hem-LB-BA1 inhibited specific (125I-Tyr4)BB binding to NCI-H1299 cells, which have BB2 receptors (R), with IC50 values of 15 and 25 nM, respectively. Addition of Hem-LA-BA1 and Hem-LB-BA1 to Fura-2 AM loaded cells containing BB2R, caused elevated cytosolic Ca2+. In a growth assay, Hem-LA-BA1 and Hem-LB-BA1 inhibited the proliferation of NCI-H1299 cells. Dol-succinamide (Dols)-LD-BA1 and Dols-LE-BA1 bound with high affinity to NCI-H1299 cells and elevated cytosolic Ca2+, but did not inhibit the proliferation of NCI-H1299 cells. Also, Hem-LA-BA1 inhibited 125I-DTyr-Gln-Trp-Ala-Val-betaAla-His-Phe-Nle-NH2 (BA2) binding to Balb/3T3 cells transfected with BB1R or BB2R as well as with BRS-3 with IC50 values of 130, 8, and 540 nM, respectively. These results show that Hem-BB conjugates are cytotoxic for cancer cells containing BB2R.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336841      PMCID: PMC2695325          DOI: 10.1016/j.lfs.2008.01.019

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  32 in total

Review 1.  Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.

Authors:  L H Patterson; S R McKeown; T Robson; R Gallagher; S M Raleigh; S Orr
Journal:  Anticancer Drug Des       Date:  1999-12

2.  Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules.

Authors:  Girija Krishnamurthy; Wendy Cheng; Mei-Chu Lo; Ann Aulabaugh; Vladimir Razinkov; WeiDong Ding; Frank Loganzo; Arie Zask; George Ellestad
Journal:  Biochemistry       Date:  2003-11-25       Impact factor: 3.162

3.  High levels of intracellular bombesin characterize human small-cell lung carcinoma.

Authors:  T W Moody; C B Pert; A F Gazdar; D N Carney; J D Minna
Journal:  Science       Date:  1981-12-11       Impact factor: 47.728

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

Review 5.  Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.

Authors:  A Nagy; A V Schally
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

6.  Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).

Authors:  Jean Claude Reubi; Sandra Wenger; Jacqueline Schmuckli-Maurer; Jean-Claude Schaer; Mathias Gugger
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.

Authors:  Timothy J Hoffman; Hariprasad Gali; C Jeffrey Smith; Gary L Sieckman; Donald L Hayes; Nellie K Owen; Wynn A Volkert
Journal:  J Nucl Med       Date:  2003-05       Impact factor: 10.057

8.  Bombesin, somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma.

Authors:  S M Wood; J R Wood; M A Ghatei; Y C Lee; D O'Shaughnessy; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

9.  Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.

Authors:  Terry W Moody; Samuel A Mantey; Tapas K Pradhan; Michael Schumann; Tomoo Nakagawa; Alfredo Martinez; Joseph Fuselier; David H Coy; Robert T Jensen
Journal:  J Biol Chem       Date:  2004-03-11       Impact factor: 5.157

10.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.

Authors:  F Cuttitta; D N Carney; J Mulshine; T W Moody; J Fedorko; A Fischler; J D Minna
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

View more
  8 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 3.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

Review 4.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

Review 5.  Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.

Authors:  Yosi Gilad; Michael Firer; Gary Gellerman
Journal:  Biomedicines       Date:  2016-05-26

Review 6.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

7.  Scorpion peptides: potential use for new drug development.

Authors:  Bennasr Hmed; Hammami Turky Serria; Zeghal Khaled Mounir
Journal:  J Toxicol       Date:  2013-06-15

Review 8.  Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-29       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.